Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$9.54 USD
+0.11 (1.17%)
Updated May 17, 2024 04:00 PM ET
After-Market: $9.55 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ATXS 9.54 +0.11(1.17%)
Will ATXS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ATXS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATXS
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Is a Surprise Coming for Astria Therapeutics (ATXS) This Earnings Season?
ATXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Suncor (SU) Q3 Earnings Preview: What Investors Need to Know
Will NexTier Merger Boost Patterson-UTI's (PTEN) Q3 Earnings?
Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug
Other News for ATXS
Astria TherapeuticS GAAP EPS of -$0.38 misses by $0.02
Wedbush Sticks to Its Buy Rating for Astria Therapeutics (ATXS)
Astria Therapeutics: A Strong Buy on Innovative HAE Treatment and Strategic Growth
Buy Rating for Astria Therapeutics: Promising STAR-0215 Outpaces Competitors with Strategic Trials and Market Potential
Astria Therapeutics: Strong Buy Rating on Robust Finances and Promising Clinical Trials